CAR T-cells vs. bispecific antibodies as third- or later-line treatment for relapsed/refractory follicular lymphoma: a literature review and meta-analysis.

Front Immunol · 2025 · PMC12515661 · PMID 41089680

Europe PMC DOI

hedged sentence

0.0670

closest p · 1.3× alpha

0.0670

boldest claim

The sentences

did not reach statistical significancep=0.067so close (0.05 < p ≤ 0.1)

However, when CAR T-cell therapy was included in the multivariate model, the effect did not reach statistical significance (odds ratio 0.1278 [95% CI -0.0091 to 0.2647]; p=0.067), suggesting that CAR T-cell therapy is not an independent predictor of CR rates.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.